Share on LinkedInShare on LinkedIn

ARTICLE · 05 SEPTEMBER 2007

Scant Showing Of Future Plans To Infringe Insufficient For Declaratory Judgment

The U.S. Court of Appeals for the Federal Circuit affirmed the dismissal of Nucleonics’ declaratory judgment counterclaims for patent invalidity and unenforceability since no legal threat existed where Benitec voluntarily dismissed its patent infringement claims and granted a covenant not to sue Nucleonics.

United StatesIntellectual Property

The U.S. Court of Appeals for the Federal Circuit affirmed the dismissal of Nucleonics’ declaratory judgment counterclaims for patent invalidity and unenforceability since no legal threat existed where Benitec voluntarily dismissed its patent infringement claims and granted a covenant not to sue Nucleonics. Benitec Australia, Ltd. v. Nucleonics, Inc., Case No. 06-1122 (Fed. Cir., July 20, 2007) (Whyte, Dist. J.(sitting by designation), Dyk, J., dissenting).

Benitec’s infringement action involved U.S. Patent No. 6,573,099 (the ’099 patent) for RNA-interference technology that prevents expression of disease-causing genes. Nucleonics answered and moved to dismiss Benitec’s premature complaint. Nucleonics’ allegedly infringing conduct involved clinical testing for FDA submission on human disease treatment—exempt from infringement under 35 U.S.C. §271(e)(1). Nucleonics later amended its counterclaims to allege invalidity and unenforceability of the ’099 Patent.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from